Pyruvate kinase deficiency

WikiDoc Resources for Pyruvate kinase deficiency
Articles
Most recent articles on Pyruvate kinase deficiency Most cited articles on Pyruvate kinase deficiency Review articles on Pyruvate kinase deficiency Articles on Pyruvate kinase deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Pyruvate kinase deficiency Images of Pyruvate kinase deficiency Photos of Pyruvate kinase deficiency Podcasts & MP3s on Pyruvate kinase deficiency Videos on Pyruvate kinase deficiency
Evidence Based Medicine
Cochrane Collaboration on Pyruvate kinase deficiency Bandolier on Pyruvate kinase deficiency TRIP on Pyruvate kinase deficiency
Clinical Trials
Ongoing Trials on Pyruvate kinase deficiency at Clinical Trials.gov Trial results on Pyruvate kinase deficiency Clinical Trials on Pyruvate kinase deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Pyruvate kinase deficiency NICE Guidance on Pyruvate kinase deficiency NHS PRODIGY Guidance FDA on Pyruvate kinase deficiency CDC on Pyruvate kinase deficiency
Books
Books on Pyruvate kinase deficiency
News
Pyruvate kinase deficiency in the news Be alerted to news on Pyruvate kinase deficiency News trends on Pyruvate kinase deficiency
Commentary
Blogs on Pyruvate kinase deficiency
Definitions
Definitions of Pyruvate kinase deficiency
Patient Resources / Community
Patient resources on Pyruvate kinase deficiency Discussion groups on Pyruvate kinase deficiency Patient Handouts on Pyruvate kinase deficiency Directions to Hospitals Treating Pyruvate kinase deficiency Risk calculators and risk factors for Pyruvate kinase deficiency
Healthcare Provider Resources
Symptoms of Pyruvate kinase deficiency Causes & Risk Factors for Pyruvate kinase deficiency Diagnostic studies for Pyruvate kinase deficiency Treatment of Pyruvate kinase deficiency
Continuing Medical Education (CME)
CME Programs on Pyruvate kinase deficiency
International
Pyruvate kinase deficiency en Espanol Pyruvate kinase deficiency en Francais
Business
Pyruvate kinase deficiency in the Marketplace Patents on Pyruvate kinase deficiency
Experimental / Informatics
List of terms related to Pyruvate kinase deficiency

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Pyruvate Kinase Deficiency is an inherited autosomal recessive genetic disorder which affects the survival of red blood cells. A variety of mutations can lead to lowered production, activity, or stability of pyruvate kinase, an enzyme essential to glycolysis. A total lack of this enzyme's activity will be lethal. Because the ability of erythrocytes to manufacture ATP depends on glycolysis, the cells become deficient in energy and unable to maintain the activity of the basolateral Na⁺/K⁺-ATPase. This will result in an increase in intracellular [Na⁺] which will cause water to diffuse passively into the red blood cell (RBC) and will lead to swelling. This swelling will lead to lysis of the RBCs and an increase in plasma bilirubin. The increase in plasma bilirubin will lead to jaundice and the lysis of the RBCs will lead to hemolytic anemia. The buildup of reaction intermediates can also increase the level of 2,3-bisphosphoglycerate in the cells and affect tissue oxygenation. This will cause a "right shift" in the hemoglobin oxygen saturation curve, implying a decreased oxygen affinity for the hemoglobin and earlier oxygen unloading than under normal conditions.

Clincally, this disorder is most common glycolytic enzyme deficiency, that will lead to hemolytic anemia.

Most affected individuals do not require treatment. Individuals who are most severely affected may die in utero of anemia or may require blood transfusions or splenectomy, but most of the symptomatology is limited to early life and times of physiologic stress or infection.

Red blood cells use glycolysis as their sole energy source. In pyruvate kinase deficiency, the last step (phosphoenolpyruvate converted to pyruvate) of glycolsis is unable to occur. A discrepancy between red blood cell energy requirements and ATP generating capacity produces irreversible membrane injury resulting in cellular distortion, rigidity, and dehydration. This leads to premature erythrocyte destruction by the spleen and liver.

Treatment

Treatment can include a blood transfusion or removal of the spleen. Treatment is usually effective in reducing the severity of the symptoms. Template:SIB Template:WH Template:WS